Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 10/23 11:50:46 am
84.64 EUR   +0.99%
10/22 HISTOGENICS : Movers & Shakers
10/19 SANOFI : Pasteur and VaxServe’s Lackawanna County Community F..
10/19 SANOFI : - More than 30 Presentations of New Investigational Data fr..
News SummaryMost relevantAll newsSector newsTweets

Reports Outline Medicinal Chemistry Study Results from Sanofi (Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum)

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:30pm CEST

By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Medicinal Chemistry have been published. According to news reporting originating in Frankfurt, Germany, by NewsRx journalists, research stated, "The scientific advances being made across all disciplines are creating ever-increasing opportunities to enhance our knowledge of biological systems and how they relate to human disease. One of the central driving forces in discovering new medicines is medicinal chemistry, where the design and synthesis of novel compounds has led to multiple drugs."

The news reporters obtained a quote from the research from Sanofi, "Chemical biology, sitting at the interface of many disciplines, has now emerged as a major contributor to the understanding of biological systems and is becoming an integral part of drug discovery. Bringing chemistry and biology much closer and blurring the boundaries between disciplines is creating new opportunities to probe and understand biology; both disciplines play key roles and need to join forces and work together effectively to synergize their impact. The power of chemical biology will then reach its full potential and drive innovation, leading to the discovery of transformative medicines to treat patients."

According to the news reporters, the research concluded: "Advances in cancer biology and drug discovery highlight this potential."

For more information on this research see: Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. Cell Chemical Biology, 2017;24(9):1058-1065. Cell Chemical Biology can be contacted at: Cell Press, 50 Hampshire St, Floor 5, Cambridge, MA 02139, USA (see also Medicinal Chemistry).

Our news correspondents report that additional information may be obtained by contacting A.T. Plowright, Sanofi Aventis Deutschland GmbH, Integrated Drug Discovery, D-65926 Frankfurt, Germany. Additional authors for this research include C. Ottmann, M. Arkin, Y.P. Auberson, H. Timmerman and H. Waldmann.

Keywords for this news article include: Frankfurt, Germany, Europe, Medicinal Chemistry, Chemical Biology, Chemicals, Sanofi.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
10/22 HISTOGENICS : Movers & Shakers
10/20 PEREGRINE PHARMACEUTICALS : Pharma (PPHM) Appoints Mark Bamforth to Board
10/20 PEREGRINE PHARMACEUTICALS : Announces Appointment of Mark R. Bamforth to Board o..
10/19 SANOFI : Pasteur and VaxServe’s Lackawanna County Community Fundraiser Ma..
10/19 SANOFI : - More than 30 Presentations of New Investigational Data from Sanofi : ..
10/18 SANOFI : earmarks 170m for new French vaccines facility
10/18 SANOFI SA (ADR)(NYSE : SNY), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Dupixen..
10/18 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Phase 2 Study Results f..
10/18 SANOFI : and Regeneron Announce Positive Phase 2 Study Results for Dupilumab
10/17 Regeneron-Sanofi drug succeeds mid-stage study
More news
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
10/17 The Medicines Company May Not Be The Best Investment In 2017
10/16 Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients ..
10/16 MANNKIND CORPORATION : Can Afrezza Improved Labeling Fuel A Successful Comeback?
Financials (€)
Sales 2017 36 177 M
EBIT 2017 9 601 M
Net income 2017 8 158 M
Debt 2017 4 345 M
Yield 2017 3,61%
P/E ratio 2017 12,85
P/E ratio 2018 17,48
EV / Sales 2017 3,05x
EV / Sales 2018 2,97x
Capitalization 106 B
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 28
Average target price 86,7 €
Spread / Average Target 3,4%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI8.99%124 704
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116